For the many and the few: bringing ASO therapies to both mainstream and nano-rare indications

Stanley Crooke

12 March 2025

Interview

Addressing regulatory hurdles for individualized mRNA cancer immunotherapies: insights into the MHRA’s new guidance for developers

Francis Galaway

11 February 2025

Interview

What removing the DNA synthesis bottleneck means for the future of drug discovery and development

Elizabeth Wood

14 January 2025

Interview

Bringing the power of DNA synthesis to bear in the field of synthetic biology

Paul Freemont

09 January 2025

Interview

Exploring alternatives to plasmid DNA for safer, higher quality gene therapy

Nafiseh Nafissi

20 December 2024

Interview

Tackling the key challenges for therapeutic oligonucleotide manufacture: cost, scale, and sustainability

Ben Andrews

26 November 2024

Interview

Improving lipid nanoparticle formulations for targeted delivery of genome editors

Rohit Sharma

05 November 2024

Interview

Understanding DNA starting material for mRNA production

Lawrence Thompson

30 October 2024

Interview

Shifting to non-viral in vivo therapies to enhance global patient access to genetic medicines

Hari Pujar

27 September 2024

Interview

Advancing mRNA production through platform and continuous process development

Zoltan Kis

25 September 2024

Interview

Advancing treatment of genetic diseases through engineered tRNA therapeutics

William Kiesman

24 September 2024

Interview

Advancing delivery of RNA therapeutics with cationizable xenopeptides

Ernst Wagner

24 September 2024

Interview

Delving into the unknowns of mRNA-LNP formulation and characterization

Ramesh Marasini

15 July 2024

Interview

From bench to bedside: advancing mRNA therapies for cardiovascular diseases

Ajit Magadum

27 June 2024

Interview

Harnessing the potential of AI/ML to expand the horizons of the oligonucleotide therapeutics field

Arijit Bhowmick

27 June 2024

Interview

Taking a high-throughput approach to enhancing the target specificity and stability of nanoparticles

Chun-Wan Yen, Yuchen Fan

20 June 2024

Interview

Exploring issues and opportunities in the development of platform technologies for oligonucleotide manufacturing

Jeske Smink

03 June 2024

Interview

Evolution of mRNA-based vaccines: a regulator’s view

Ka-Wai Wan

22 May 2024

Interview

Moving mRNA–LNP therapeutics towards the clinic: overcoming myths and misconceptions to solve the specificity challenge

Ansgar Santel, Jörg Kaufmann

21 May 2024

Interview

Pushing the boundaries of siRNA targeting and delivery

Merle Fuchs

20 March 2024

Interview

Key challenges and future opportunities for LNP-based delivery

Julien Couture-Senécal

19 March 2024

Interview